rNRG4 suppresses breast cancer organoid progression (IMAGE)
Caption
A) Establishment of reproducible breast cancer organoid model. The tumor tissue obtained from the patient was washed and cut into pieces of less than 1 mm in diameter using dissecting scissors. The minced tissue was then resuspended in culture medium. (B) Morphology of P0 breast cancer organoids (BCO) treated with 50 or 100 ng/mL rNRG4 for 72 h. (C) qPCR analysis of the proliferation (Pcna, Ki67) and angiogenically related genes in BCO treated with 50 or 100 ng/mL rNRG4. (D) qPCR analysis of the mesenchymal (Cdh2, fibronectin, vimentin, Zeb1, Snail) and epithelial (Cdh1, Zo-1) related genes in BCO treated with 50 or 100 ng/mL rNRG4. (E) The schematic outlines that NRG4 from normal iWAT activates ERBB4 on cancer cells, leading to pERBB4 cleavage and complex formation with pYAP1, preventing YAP1 nuclear translocation and inhibiting tumor metastasis. The data were presented as mean ± standard deviation. ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.
Credit
Saijun Wang, Mingwei Guo, Lingyun Xu, Jiaming Xue, Shuai Chen, Ke Xu, Yan Zhou, Aihua Gu, Wei Gao, Jianwei Zhou, Yi Zhang, Liming Tang, Dongmei Wang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND